Verici Dx (LSE:VRCI) has completed an £8.75 million fundraising, giving the kidney transplant diagnostics company fresh capital as orders for its commercial test continue to climb across US transplant centres. The placing and retail offer, launched on 8 October 2026 and confirmed as complete on 13 October, came shortly after half-year results showed rising test volumes alongside a wider loss and a modest cash balance.

What the company does

Verici Dx develops clinical diagnostic tests for kidney transplant patients. Its tests use artificial intelligence-assisted analysis of RNA signatures to assess immune response, injury, rejection and the risk of graft failure. Its commercial product is Tutivia, while its pipeline includes a pre-transplant risk assessment test, the Protega test and a new product called TranscripTx. The company focuses mainly on the US market.

Latest developments

The fundraising, comprising a placing and a WRAP retail offer, follows a smaller equity raise in June 2026 that brought in gross proceeds of about £2.6 million. The completion announcement named Singer Capital Markets and Oberon Capital as joint brokers and bookrunners, and trading in the shares resumed on 13 October after the capital access window closed.

In the half-year report published on 30 September 2026, the company said Tutivia orders rose to 433 in the second quarter from 392 in the first, with third-quarter orders expected to exceed 500. First-half orders of 825 compared with 1,173 for the whole of 2025. Some 35 transplant centres now use Tutivia, which the company estimates represent about 23% of annual US kidney transplants, and average reimbursement is around $2,300 per test.

There has also been regulatory and product progress. Protega received an additional CPT code effective from 1 October 2026, which the company described as a key step towards commercial reimbursement. A study published in June estimated that its pre-transplant test could produce potential US healthcare savings of more than $191 million over two years across standard-risk kidney transplants. In September the company announced that TranscripTx would launch in the fourth quarter, and in August it signed a certified service provider agreement with Olink.

Financial picture

Revenue for the six months to 30 June 2026 was $1.8 million, compared with $1.9 million a year earlier, when the figure included $0.75 million of licensing income. Tutivia testing revenue rose 53%. The loss for the period widened to $4.0 million from $3.1 million, and cash stood at $2.4 million at the end of June after an operating outflow of $3.8 million. The company does not pay a dividend. Chief executive Sara Barrington described the half as a positive and progressive period.

Sector and index context

Verici Dx is one of several early-stage diagnostics developers on the FTSE AIM All Share Index. Companies in this field typically need repeated funding while they build clinical evidence, secure reimbursement codes and persuade clinicians to adopt new tests.

Key risks

The company remains loss-making and has relied on regular equity raises, which dilute shareholders. Its half-year report identified going concern as a key judgement, with forecasts dependent on uncertain revenue and spending timing. Reimbursement decisions, clinician adoption, competition from other transplant diagnostics and execution in the US market are further risks.

What to watch next

Management expects further strong order growth in the fourth quarter as newly onboarded centres become repeat users. Investors will watch whether third-quarter orders exceed 500 as guided, the launch of TranscripTx, and progress towards revenue from the pre-transplant test and Protega, which the company expects to contribute from 2027.